Report
Pharma Mar : Higher R&D spending drives Q2 2022 results below estimates
>Q2 2022 numbers showed higher sales and royalties from Zepzelca - Total revenues receded slightly -1% y-o-y in Q2 2022 (vs +2% in Q1 2022), in line with our estimates. Biopharma sales decreased 2% y-o-y in Q2 2022 (compared to +1% in Q1) reflecting lower Yondelis pricing (-14% y-o-y vs -7% in Q1), an impact which was offset by Zepzelca sales in Europe under the temporary use authorisation programme (ATU). Sales at the diagnostic division remain solid (+7% y-o-y in Q2...
Underlying
Pharma Mar SA
Provider
Oddo BHF
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Isabel Carballo
Other Reports on these Companies
Other Reports from Oddo BHF
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.